Artios Information

Artios is on a mission to kill cancer by exploiting DNA damage response (DDR) and repair pathways that are leveraged by cancer cells to promote their survival. Our specialized DcoDeR platform integrates Artios’ leadership capabilities, expertise and experience in DNA damage biology and drug discovery to systematically discover and develop medicines targeting the totality of the DDR. We have built an extensive DDR focused pipeline designed to address areas of high unmet needs across solid tumour indications including our ATR inhibitor, ART0380, and our Polθ inhibitor ART6043, as monotherapy and combination treatments. Together with our strategic partnerships with Merck KGaA and Novartis, and research collaborations with premiere institutions like Cancer Research UK, The Institute of Cancer Research, The Netherlands Cancer Institute, and the Crick Institute we are pioneering validated approaches to DDR drug discovery. Visit our website at https://www.artios.com/ for more information about the company and our pipeline. Artios is based at the Babraham Campus in Cambridge, UK. If you are interested in working at Artios and have the qualities to be part of our team, please submit your application via our website. We are also very mindful of scams that involve recruitment. At this time please note we are currently not working with any third parties in India for recruitment.